The shareholders of Hansa Medical AB (publ) are summoned to attend the Annual General Meeting on May 11th, 2016, at 17.00 CET at the auditorium next to the company’s premises, Scheelevägen 22, Lund, Sweden. The shareholders of Hansa Medical AB (publ) are hereby summoned to attend the Annual General Meeting (“AGM”) on May 11th, 2016, at 17.00 CET at the auditorium next to the company’s premises, Scheelevägen 22, Lund, Sweden. Registration starts at 16.30 CET and will be possible until the meeting starts. Refreshments will be served after the meeting. Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per May 4th, 2016, and who, no later than May 4th, 2016 at 12.00 CET, give notice to the company of their intent to participate at the AGM have a right to participate in the AGM. Notice to participate shall be given in writing to Hansa Medical AB, c/o Fredersen Advokatbyrå AB, Turning Torso, 211 15 Malmö, by e-mail to hansamedical@fredersen.se or by fax to +46-40-232003. The notice shall contain the shareholder’s name, personal identity number or registration number and daytime telephone number and, where applicable, the number of advisors (maximum two). After giving notice of participation the shareholder will receive a confirmation. If no confirmation is received, notice has not been duly given. A shareholder whose shares are registered under the name of a nominee must temporarily register his/her shares in his/her own name with Euroclear Sweden AB to be entitled to participate in the AGM. Such registration must be in effect no later than May 4th, 2016 and should be requested with the nominee well in advance. Proxy If a shareholder wishes to be represented by proxy, a power of attorney shall be issued to the proxy. The power of attorney is to be in writing, dated and duly signed by the shareholder. If the shareholder is a legal entity, a copy of the registration certificate or, if no such document exists, equivalent documentation shall be included with the notification. The documentation shall prove the right of the person that has signed the power of attorney to appoint proxy. To facilitate registration at the AGM, please provide the power of attorney in original as well as registration certificate and other documents of authority to Fredersen Advokatbyrå to the address above preferably before 12.00 CET on May 4th, 2016. If the power of attorney and other authorization documents have not been submitted in advance, the power of attorney in the original and other authorization documents must be presented at the AGM. Power of attorney forms are available at the company and on the company’s website, www.hansamedical.com, and will be sent upon request to any shareholder who states their postal address. Proposal of agenda 0 Opening of the meeting 1 Election of chairman of the meeting 2 Preparation and approval of the voting register 3 Approval of the agenda 4 Election of one or two persons to attest the minutes 5 Determination as to whether the meeting has been duly convened 6 Update of the CEO 7 Presentation of the annual report and the Auditor’s report as well as the group accounts and the Auditor’s report for the group 8 Resolution a) on adoption of the profit and loss account and the balance sheet as well as of the consolidated profit and loss account and the consolidated balance sheet b) on allocation of the company’s loss as set forth in the adopted balance sheet c) on discharge from liability for the Board Members and the CEO 9 Resolution as to the number of Board Members, Auditors and Deputy Auditors 10 Resolution on the remuneration to the Board of Directors and Auditor 11 Election of Board Members, Chairman of the Board, Auditors and Deputy Auditors 12 Resolution on principles for the Nomination Committee 13 Resolution on guidelines for remuneration to senior management 14 Closing of the meeting Resolution proposals Dividend (item 8b) The Board of Directors proposes that no dividend will be paid for the financial year 2015. Election of Chairman of the Meeting, Board of Directors, Chairman of the Board and Auditor, decisions regarding Remuneration and Guidelines for the Nomination Committee (item 1, 9-12) The Nomination Committee, composed by Anders Blom (Nexttobe AB), chairman, Fredrik Bogren (Farstorps Gård AB) and Astrid Samuelsson (Handelsbanken Fonder), proposes as follows: - Chairman of the Meeting: Eddie Juhlin - Number of Board Members: six members - Number of Auditors: one registered accounting firm - Remuneration: SEK 500,000 to the Chairman of the Board and SEK 110,000 each to the other Board Members except for Angelica Loskog. Remuneration to the Board committees: SEK 40,000 to the chairman and SEK 30,000 each to the other Board Members in the Audit Committee, SEK 40,000 to the chairman and SEK 25,000 each to the other Board Members in the Remuneration Committee and SEK 25,000 each to the Board Members in the Scientific Committee. A Board Member may, if it is in accordance with current tax legislation and provided that it is cost neutral for the company, be given the possibility to invoice the remuneration from his/her own company, provided that the company is registered for corporate tax (sw. F-skatt). Social contributions fees and VAT will be added to such remuneration invoiced by Board Member within a business operation - Remuneration to the Auditors: according to an approved account - Board Members: re-election of Stina Gestrelius, Hans Schikan, Birgit Stattin Norinder and Per Olof Wallström and election of Angelica Loskog and Ulf Wiinberg; it is noted that Cindy Wong and Anders Blom have declined re-election - Chairman of the Board: Ulf Wiinberg - Auditor: re-election of KPMG AB - That the following instruction shall apply for the Nomination Committee for the AGM 2016: The Nomination Committee shall consist of representatives for the three largest, in terms of votes, registered shareholders as per August 31st, 2016. Should such shareholder not wish to appoint a member, the largest shareholders, in terms of votes, thereafter shall be invited to appoint members of the Nomination Committee, until three members have been appointed. The names of the members of the Nomination Committee shall be made public no later than six months prior to the AGM of 2017. The Nomination Committee shall appoint the member representing the largest shareholder as chairman, unless the Nomination Committee decides otherwise. Should any of the members of the Nomination Committee, before the assignment of the Nomination Committee has been fulfilled, resign or no longer represent the shareholder who appointed that member, such member shall be replaced by a new member appointed by that shareholder. Should any shareholder not represented in the Nomination Committee be larger, in terms of votes, than another shareholder represented in the Nomination Committee, the larger shareholder shall be entitled to appoint a member to the Nomination Committee, whereby the member representing the smallest, in terms of votes, shareholder shall leave the Nomination Committee. The term of office for the Nomination Committee shall be until a new Nomination Committee has been appointed. If necessary, the company shall compensate reasonable costs, which the Nomination Committee has deemed necessary for the fulfilment of its assignment. The Nomination Committee shall be entitled to call in one or more additional members, who shall not be entitled to vote. The members of the Nomination Committee shall not be entitled to any remuneration from the company for their work. The Nomination Committee shall present proposals for Chairman of the Meeting, Board Members, Chairman of the Board, remunerations to the Board, auditors, remuneration to the auditors and the process of appointing a new Nomination Committee for the AGM of 2017. The Nomination Committee shall follow and fulfil the assignments set out in the Swedish Corporate Governance Code. Angelica Loskog, born 1973, is Doctor of Philosophy (Faculty of Medicine) and adjunct professor at the Department of Immunology, Genetics and Pathology at Uppsala University. Loskog is scientific advisor to Nexttobe AB, CEO of Lokon Pharma AB, as well as chairman of Vivolux AB and Repos Pharma AB. She is independent of the company and its management but not to major shareholders of Hansa Medical. She owns no shares in the company. Ulf Wiinberg, born 1958, has extensive experience in the pharmaceutical industry. Wiinberg has previously been CEO of H. Lundbeck A/S and has held senior positions at Wyeth. Wiinberg is a Board member of Alfa Laval AB and Nestle Health and Science and chairman of the Board of Avillion, and is nominated for the Board of directors of the Belgian pharmaceutical company UCB. He is independent of the company and its senior management and independent of major shareholders of Hansa Medical. He owns 75 000 shares in the company. Resolution on guidelines for remuneration to senior management (item 13) The guidelines proposed by the Board of Directors entail that senior management will be offered remuneration that is competitive and on market terms. The level of the remuneration for the individual manager shall be based on factors such as position, expertise, experience and performance. The remuneration consists of a fixed salary and pension benefits and, in addition, may consist of variable salary, severance compensation and non-monetary benefits. The variable salary shall be based on the achievement of quantitative and qualitative targets and should not exceed 50 % of the annual fixed salary. Salary during the notice of termination period and severance compensation shall be possible in a total maximum amount of 24 monthly salaries. It is proposed that the Board of Directors be authorized to deviate from the guidelines where special cause exists in an individual case. Other information When this notice to attend the AGM was issued, the total number of shares and votes in the company was 32 412 003. The company does not own any of its own shares. Annual report, Auditor’s report, the Auditor´s report regarding the application of the guidelines considering remuneration to the senior management adopted by the AGM 2015, complete proposals and supporting documents will be available at the company and on the company’s website www.hansamedical.com, during a period of not less than three weeks prior to the AGM. Copies of the documents will be sent upon request to any shareholder stating his/her postal address. Upon request by any shareholder, the Board of Directors and the CEO shall at the AGM provide information regarding any circumstance which may affect the assessment of a matter on the agenda and any circumstance which may affect the assessment of the company’s or any subsidiary’s financial position, provided that such information in the opinion of the Board of Directors and the CEO may be given without causing significant harm to the company, or any subsidiary. The duty to provide information shall apply also to the company’s relationship to other group companies. NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail. Lund, April 2016 Hansa Medical AB (publ) The Board of Directors For further information, please contact: Hansa Medical AB Göran Arvidson, CEO Mobile: 46 70-633 30 42 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About Hansa Medical AB Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm. The information in this notice is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on April 12, 2016 at 8.30 CET.
Notice of Annual General Meeting of Hansa Medical AB (publ)
Top 10 Most Recent News Articles
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape
Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...
Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small
Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...
Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play
Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...
Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial
Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...
Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings
American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....
Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens
Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...
Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny
Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...
Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion
Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...
Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion
Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...
Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching
Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...
Continue ReadingTop 5 Most Recently Viewed Articles
New Leadership at KeyCorp: A Strategic Move for Risk Management
KeyCorp Welcomes Mohit Ramani as Chief Risk Officer KeyCorp (NYSE: KEY), a prominent figure in the bank-based financial services industry, has made an important decision by announcing the appointment of Mohit (Mo) Ramani as its new Chief Risk Officer. This notable addition to the executive leadership team is seen as a strategic step towards enhancing the company's risk...
Continue Reading
Quaternary Ammonium Salts Market Expanding: Insights Ahead
Exploring the Growth of the Quaternary Ammonium Salts Market The global quaternary ammonium salts market is on a remarkable growth trajectory, anticipated to reach a valuation of US$ 1,088.0 Million by the year 2034. With a robust CAGR of 5.9% from 2024 to 2034, this market is driven by increasing consumer awareness regarding hygiene and safety. Factors Driving Market...
Continue Reading
Generac's Upcoming Earnings: Key Details and Expectations
Generac Prepares for Earnings Release and Conference Call Generac Holdings Inc. (NYSE: GNRC), known as a prominent leader in energy technology solutions, is gearing up for an important announcement. The company plans to unveil its fourth quarter and full-year 2024 financial results just before the market opens. The anticipated date for this release is set for an upcoming...
Continue Reading
AAVantgarde Ready for Key Presentations at EURetina 2025
Significant Presentation at EURetina 2025 AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions...
Continue Reading
Investing in WisdomTree Funds: Insights on Value and Performance
Understanding the Value of WisdomTree Funds WisdomTree is known for its innovative approach to exchange-traded funds (ETFs). As investors seek ways to maximize their asset portfolios, understanding the net asset values (NAVs) of these funds becomes essential. In this article, we delve into various funds offered by WisdomTree, highlighting their date of valuation and key...
Continue Reading